Knight Therapeutics Inc. (T:GUD)

Business Focus: Proprietary & Advanced Pharmaceuticals

Get the company report for the most recent outlook updated daily

Apr 09, 2024 07:30 am ET

Knight to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-US) specialty pharmaceutical company, announced today that Samira Sakhia, President and Chief Executive Officer, is scheduled to present a corporate update at the Bloom...

Mar 28, 2024 11:03 am ET

Knight Therapeutics Inc. ranks on The Globe and Mail’s fifth-annual Women Lead Here benchmark of executive gender diversity

Knight Therapeutics Inc. (TSX: GUD) (“Knight” or “the Company”) is pleased to announce it will be recognized on The Globe and Mail’s 2024 Report on Business magazine’s fifth annual Women Lead Here list. This annual editorial benchmark identifies...

Mar 21, 2024 07:30 am ET

Knight Therapeutics Reports Fourth Quarter and Year-End 2023 Results

Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a leading pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its fourth quarter and year ended December 31, 2023. All currency amounts are in...

Mar 14, 2024 07:30 am ET

Notice of Knight Therapeutics' Fourth Quarter and Year End 2023 Results Conference Call

Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its fourth quarter and year end 2023 financial results on Thursday, March 21, 2024 prior to market opening. Following the...

Feb 29, 2024 07:30 am ET

Knight Therapeutics Announces Launch of Minjuvi® in Brazil

Knight Therapeutics Inc., (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today the launch of Minjuvi® (tafasitamab) by its Brazilian affiliate, United Medical Ltda. Minjuvi® is indicated in combination...

Feb 28, 2024 07:30 am ET

Knight Therapeutics Inc. Celebrates its First Decade of Success

Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that it is marking its 10-year anniversary, and celebrating a decade of expansion and growth. Since its inception on...

Feb 21, 2024 05:30 pm ET

Knight Therapeutics Announces Regulatory Submission of Fostamatinib in Brazil

Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltda., has submitted a marketing authorization application to ANVISA, the...

Feb 06, 2024 07:30 am ET

Knight Therapeutics Announces Launch of Bijuva® in Canada

Knight Therapeutics Inc., (TSX: GUD) ("Knight"), a Pan-American (ex-USA) specialty pharmaceutical company, announced today the launch of BIJUVA® (estradiol and progesterone) capsules in Canada. BIJUVA® is indicated for the treatment of moderate to...

Jan 25, 2024 07:30 am ET

Knight Therapeutics Enters into Exclusive License Agreement with Amneal Pharmaceuticals for IPX203

Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that it has entered into an exclusive license agreement with Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) ("Amneal"), granting...

Jan 04, 2024 07:30 am ET

Knight Therapeutics Announces Product Launch for IMVEXXY® in Canada

Knight Therapeutics Inc., (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today the launch of IMVEXXY® in Canada. IMVEXXY® (estradiol vaginal inserts) is approved for the treatment of postmenopausal...

Dec 19, 2023 07:30 am ET

Knight Therapeutics Enters into Exclusive License Agreement with Supernus Pharmaceuticals for Qelbree® (viloxazine) in Canada

Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that it has entered into an exclusive license agreement with Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) ("Supernus"), a...

Nov 09, 2023 07:30 am ET

Knight Therapeutics Reports Third Quarter 2023 Results

Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a leading pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its third quarter ended September 30, 2023. All currency amounts are in thousands...

Nov 02, 2023 07:30 am ET

Notice of Knight Therapeutics' Third Quarter 2023 Results Conference Call

Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its third quarter 2023 financial results on Thursday, November 9, 2023 prior to market opening. Following the release,...

Oct 16, 2023 07:30 am ET

Knight Therapeutics Announces CMED Price Approval of Minjuvi® (tafasitamab) in Brazil

Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltd., has received pricing approval for Minjuvi® (tafasitamab) from the Drugs...

Oct 10, 2023 04:45 pm ET

Knight Therapeutics Announces Regulatory Submission of Pemigatinib in Brazil

Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltd., has submitted a marketing authorization application for pemigatinib to...

Oct 02, 2023 04:30 pm ET

Knight Therapeutics Inc. places No. 90 on The Globe and Mail's fifth-annual ranking of Canada's Top Growing Companies

Knight Therapeutics Inc. (TSX:GUD) (“Knight” or “the Company”) is pleased to announce it placed No. 90 on the 2023 Report on Business ranking of Canada’s Top Growing Companies. Canada’s Top Growing Companies ranks Canadian companies on three-year...

Aug 10, 2023 07:30 am ET

Knight Therapeutics Reports Second Quarter 2023 Results

Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a leading pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its second quarter ended June 30, 2023. All currency amounts are in thousands...

Aug 03, 2023 08:32 pm ET

Notice of Knight Therapeutics' Second Quarter 2023 Results Conference Call

Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its second quarter 2023 financial results on Thursday, August 10, 2023 prior to market opening. Following the release,...

Jul 12, 2023 07:30 am ET

Knight Announces Normal Course Issuer Bid

Knight Therapeutics Inc. (TSX:GUD) ("Knight" or the "Company "), a leading pan-American (ex-US) specialty pharmaceutical company, announced today acceptance by the Toronto Stock Exchange (the "TSX") of the Company's Notice of Intention to Make a...

Jun 02, 2023 07:30 am ET

Knight to Present at the Jefferies 2023 Healthcare Conference in New York City

Knight Therapeutics Inc. (TSX: GUD) ("Knight") a leading pan-America (ex-US) specialty pharmaceutical company, announced today that Samira Sakhia, President and Chief Executive Officer, is scheduled to present at the Jefferies 2023 Healthcare...

May 11, 2023 07:30 am ET

Knight Therapeutics Reports First Quarter 2023 Results

Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a leading pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its first quarter ended March 31, 2023. All currency amounts are in thousands...

May 10, 2023 05:42 pm ET

Knight Therapeutics Inc. announces voting results from the Annual General Meeting

Knight Therapeutics Inc. (TSX:GUD) ("Knight" or the "Corporation") a leading pan-American (ex-US) specialty pharmaceutical company, announced today the voting results from the Annual General Meeting of the Shareholders held virtually in Montreal,...

May 09, 2023 01:00 pm ET

Knight to Present at the 2023 RBC Capital Markets Global Healthcare Conference in New York City

Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a leading pan-American (ex-US) specialty pharmaceutical company, announced today that Samira Sakhia, President and Chief Executive Officer, is scheduled to participate in a fireside chat at the 2023...

May 04, 2023 07:30 am ET

Notice of Knight Therapeutics' First Quarter 2023 Results Conference Call

Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its first quarter 2023 financial results on Thursday, May 11, 2023 prior to market opening. Following the release, Knight...

Apr 18, 2023 07:30 am ET

Knight to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference

Mar 24, 2023 10:54 am ET

Knight Therapeutics Inc. ranks on The Globe and Mail’s fourth-annual Women Lead Here benchmark of executive gender diversity

Knight Therapeutics Inc. (TSX: GUD) (“Knight” or “the Company”) is pleased to announce it has been included on The Globe and Mail’s 2023 Report on Business magazine’s Women Lead Here list. This annual editorial benchmark identifies top-notch...

Mar 23, 2023 07:30 am ET

Knight Therapeutics Reports Fourth Quarter and Year-End 2022 Results

Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a leading Pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its fourth quarter and year ended December 31, 2022. All currency amounts are in...

Mar 16, 2023 07:30 am ET

Notice of Knight Therapeutics' Fourth Quarter and Year End 2022 Results Conference Call

Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its fourth quarter and year end 2022 financial results on Thursday, March 23, 2023 prior to market opening. Following the...

Dec 23, 2022 07:30 am ET

Knight Therapeutics Closes US$38.5 million Loan with IFC

Knight Therapeutics Inc., (TSX: GUD) (“Knight”) a pan-American (ex-USA) specialty pharmaceutical company, today announced that it has closed a five-year, US$38.5 million secured loan denominated in select Latin American currencies with the...

Dec 01, 2022 07:30 am ET

Knight Announces Relaunch of AKYNZEO® in Canada

Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that it has assumed full commercial activities and is relaunching oral AKYNZEO® (netupitant/palonosetron capsules) in Canada....

Nov 10, 2022 07:30 am ET

Knight Therapeutics Reports Third Quarter 2022 Results

Nov 09, 2022 06:41 pm ET

Knight to Present at Stifel Healthcare Conference

Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a leading pan-American (ex-US) specialty pharmaceutical company, is pleased to announce that Samira Sakhia, President and Chief Executive Officer, is scheduled to participate in a fireside chat at the...

Nov 03, 2022 07:30 am ET

Notice of Knight Therapeutics' Third Quarter 2022 Results Conference Call

Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its third quarter 2022 financial results on Thursday, November 10, 2022 prior to market opening. Following the release,...

Oct 06, 2022 06:12 pm ET

Knight Therapeutics Announces Regulatory Submission for Tafasitamab in Brazil

Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltd., has submitted a marketing authorization application for tafasitamab in...

Sep 23, 2022 09:44 am ET

Knight Therapeutics Inc. places No. 22 on The Globe and Mail's fourth-annual ranking of Canada's Top Growing Companies

Knight Therapeutics Inc. (TSX:GUD) (“Knight” or “the Company”) is pleased to announce it placed No. 22 on the 2022 Report on Business ranking of Canada’s Top Growing Companies. Canada’s Top Growing Companies ranks Canadian companies on...

Aug 15, 2022 07:30 am ET

Knight Therapeutics Assumes Commercial Activities and Re-Launches Exelon in Brazil

Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltda., has assumed full commercial activities and is re-launching...

Aug 11, 2022 07:30 am ET

Knight Therapeutics Reports Second Quarter 2022 Results

Aug 04, 2022 07:30 am ET

Knight to Present at the Canaccord Genuity 42nd Annual Growth Conference

Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a leading pan-American (ex-US) specialty pharmaceutical company, announced today that Amal Khouri, Chief Business Officer, is scheduled to present at Canaccord Genuity 42nd Annual Growth Conference on...

Aug 04, 2022 07:30 am ET

Notice of Knight Therapeutics' Second Quarter 2022 Results Conference Call

Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its second quarter 2022 financial results on Thursday, August 11, 2022 prior to market opening. Following the release,...

Jul 12, 2022 07:30 am ET

Knight Announces Normal Course Issuer Bid

Jul 04, 2022 07:30 am ET

Knight Therapeutics announces relaunch of AKYNZEO® in Brazil

Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltd., is assuming full commercial activities and is relaunching AKYNZEO®...

Jun 07, 2022 06:01 pm ET

Knight to Present at the 2022 BIO International Convention in San Diego

Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a leading pan-American (ex-US) specialty pharmaceutical company, announced today that Amal Khouri, Chief Business Officer, is scheduled to present at the 2022 BIO International Convention on Tuesday,...

Jun 03, 2022 07:30 am ET

Knight to Present at the Jefferies 2022 Healthcare Conference in New York City

Knight Therapeutics Inc. (TSX: GUD) ("Knight") a pan-America (ex-USA) specialty pharmaceutical company, announced today that Samira Sakhia, President and Chief Executive Officer, is scheduled to present at the Jefferies 2022 Healthcare Conference...

Jun 01, 2022 07:30 am ET

Knight Therapeutics Assumes Commercial Activities for Exelon in Colombia

Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Colombian affiliate, Biotoscana Farma S.A., is in the process of assuming full commercial activities for Exelon®...

May 24, 2022 07:30 am ET

Knight Therapeutics Enters into Exclusive License and Supply Agreements with Rigel Pharmaceuticals to Commercialize Fostamatinib in Latin America

Knight Therapeutics Inc. (TSX: GUD), a pan-American (ex-USA) specialty pharmaceutical company, today announced that it has entered into exclusive license and supply agreements with Rigel Pharmaceuticals granting Knight the rights to commercialize...

May 12, 2022 07:30 am ET

Knight Therapeutics Reports First Quarter 2022 Results

Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a leading Pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its first quarter ended March 31, 2022. All currency amounts are in thousands...

May 12, 2022 07:00 am ET

Knight Therapeutics and Helsinn Healthcare SA Enter into Exclusive License, Distribution, and Supply Agreement for Akynzeo® and Aloxi®

Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a pan-American (ex-USA) specialty pharmaceutical company, and Helsinn Healthcare SA (“Helsinn”), a fully integrated, global biopharma company with a diversified pipeline of innovative oncology assets...

May 11, 2022 09:30 pm ET

Knight to Present at the 2022 RBC Capital Markets Global Healthcare Conference in New York City

May 11, 2022 09:28 pm ET

Knight Therapeutics Inc. announces voting results from the Annual Meeting

Knight Therapeutics Inc. (TSX:GUD) ("Knight" or the "Corporation") a leading pan-American (ex-US) specialty pharmaceutical company, announced today the voting results from the Annual Meeting of the Shareholders held virtually in Montreal, Quebec...

May 05, 2022 07:30 am ET

Notice of Knight Therapeutics' First Quarter 2022 Results Conference Call

Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its first quarter 2022 financial results on Thursday, May 12, 2022 prior to market opening. Following the release, Knight...

Apr 25, 2022 06:10 pm ET

Knight to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference

Mar 25, 2022 10:10 am ET

Knight Therapeutics Inc. places on The Globe and Mail’s third-annual Women Lead Here benchmark of executive gender diversity

Knight Therapeutics Inc. (TSX: GUD) (“Knight” or “the Company”) is pleased to announce it has been recognized in The Globe and Mail’s 2022 Report on Business Women Lead Here list. This annual editorial benchmark identifies best-in-class executive...

Mar 24, 2022 07:30 am ET

Knight Therapeutics Reports Fourth Quarter and Year-End 2021 Results and Provides 2022 Revenue Guidance

Mar 17, 2022 07:30 am ET

Notice of Knight Therapeutics' Fourth Quarter and Year End 2021 Results Conference Call

Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its fourth quarter and year end 2021 financial results on Thursday, March 24, 2022 prior to market opening. Following the...

Jan 06, 2022 08:00 am ET

Knight Therapeutics Inc. Announces Approval of Halaven® in Colombia

Knight Therapeutics Inc. (TSX:GUD) (“Knight” or “the Company”) announced today that its Colombian affiliate, Biotoscana Farma S.A. has obtained INVIMA approval for Halaven® (eribulin) injection. Halaven® (eribulin) injection is indicated for the...

Jan 04, 2022 08:00 am ET

Knight Therapeutics Inc. Announces Approval of Lenvima® in Colombia

Knight Therapeutics Inc. (TSX:GUD) (“Knight” or “the Company”) announced today that its Colombian affiliate, Biotoscana Farma S.A. has obtained INVIMA approval for Lenvima® (lenvatinib), the orally available multiple receptor tyrosine kinase...

Dec 02, 2021 07:55 pm ET

Knight to Present at Stifel GMP’s The Future of Healthcare Conference

Nov 11, 2021 07:30 am ET

Knight Therapeutics Reports Third Quarter 2021

Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a leading Pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its third quarter ended September 30, 2021. All currency amounts are in thousands...

Nov 04, 2021 07:30 am ET

Notice of Knight Therapeutics' Third Quarter 2021 Results Conference Call

Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its third quarter 2021 financial results on Thursday, November 11, 2021 prior to market opening. Following the release,...

Sep 24, 2021 09:46 am ET

Knight Therapeutics Inc. places No. 27 on The Globe and Mail’s third-annual ranking of Canada’s Top Growing Companies

Knight Therapeutics Inc. (TSX:GUD) (“Knight” or “the Company”) is pleased to announce it placed No. 27 on the 2021 Report on Business ranking of Canada’s Top Growing Companies. Canada’s Top Growing Companies ranks Canadian companies on three-year...

Sep 23, 2021 07:30 am ET

Knight Therapeutics Enters into Exclusive Supply and Distribution Agreement with Incyte for Tafasitamab and Pemigatinib in Latin America

Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a pan-American (ex-USA) specialty pharmaceutical company, today announced that it has entered into a definitive agreement with Incyte Biosciences International Sàrl, the Swiss-based affiliate of...

Aug 13, 2021 07:30 am ET

Knight Therapeutics Reports Second Quarter 2021

Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a leading Pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its second quarter ended June 30, 2021. All currency amounts are in thousands...

Aug 06, 2021 07:30 am ET

Notice of Knight Therapeutics' Second Quarter 2021 Results Conference Call

Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its second quarter 2021 financial results on Friday, August 13, 2021 prior to market opening. Following the release,...

Aug 05, 2021 06:13 pm ET

Knight to Present at the Canaccord Genuity 41st Annual Growth Conference

Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a leading pan-American (ex-US) specialty pharmaceutical company, announced today that Samira Sakhia, President and Chief Operating Officer, is scheduled to present at Canaccord Genuity 41st Annual...

Jul 12, 2021 07:00 am ET

Knight Announces Normal Course Issuer Bid

Knight Therapeutics Inc. (TSX:GUD) (“Knight” or the “Company”), a leading pan-American (ex-US) specialty pharmaceutical company, announced today acceptance by the Toronto Stock Exchange (the "TSX") of the Company's Notice of Intention to Make a...

Jul 06, 2021 08:00 am ET

Knight Therapeutics Announces Health Canada Approval for NERLYNX® (Neratinib) to Treat HER2-Positive Metastatic Breast Cancer

Knight Therapeutics Inc. (TSX: GUD), (“Knight”) a pan-American (ex-USA) specialty pharmaceutical company, announced today that Health Canada has approved NERLYNX® (neratinib) in combination with capecitabine for the treatment of adult patients with...

May 26, 2021 05:10 pm ET

Knight Therapeutics Announces Closing of Previously Announced Acquisition and Exclusive License to Exelon® in Canada and Latin America

Knight Therapeutics Inc. (TSX: GUD) ("Knight") a pan-America (ex-USA) specialty pharmaceutical company, is pleased to announce that it has completed the acquisition of the exclusive rights to manufacture, market and sell Exelon® (rivastigmine...

May 25, 2021 05:30 pm ET

Knight to Present at the Jefferies 2021 Virtual Healthcare Conference

Knight Therapeutics Inc. (TSX: GUD) ("Knight") a pan-America (ex-USA) specialty pharmaceutical company, announced today that Samira Sakhia, President and Chief Operating Officer, is scheduled to present at the Jefferies 2021 Virtual Healthcare...

May 14, 2021 07:30 am ET

Knight Therapeutics Reports First Quarter 2021 Results

Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a leading pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its first quarter ended March 31, 2021. All currency amounts are in thousands...

May 13, 2021 09:50 pm ET

Knight Therapeutics Inc. announces voting results from the Annual Meeting

Knight Therapeutics Inc. (TSX:GUD) ("Knight" or the "Corporation") a leading pan-American (ex-US) specialty pharmaceutical company, announced today the voting results from the Annual Meeting of the Shareholders held virtually in Montreal, Quebec...

May 13, 2021 09:37 am ET

IIROC Trade Resumption - GUD

TORONTO, May 13, 2021 /CNW/ - Trading resumes in:

May 13, 2021 09:23 am ET

Knight Therapeutics Announces Leadership Change

Knight Therapeutics Inc. (TSX: GUD) ("Knight") is pleased to announce that Samira Sakhia will assume the role of President and Chief Executive Officer, Knight Therapeutics Inc., effective September 1, 2021. Ms. Sakhia currently serves as Knight’s...

May 13, 2021 08:24 am ET

IIROC Trading Halt - GUD

TORONTO, May 13, 2021 /CNW/ - The following issues have been halted by IIROC:

May 12, 2021 07:59 pm ET

Knight to Present at the 2021 RBC Capital Markets Global Healthcare Conference

May 07, 2021 07:30 am ET

Notice of Knight Therapeutics' First Quarter 2021 Results Conference Call

Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its first quarter 2021 financial results on Friday, May 14, 2021 prior to market opening. Following the release, Knight...

May 03, 2021 06:00 am ET

Maverix Private Equity Announces Team Additions

TORONTO, May 3, 2021 /CNW/ - Maverix Private Equity, a Toronto-based private equity firm which recently announced an inaugural USD $500 million growth-fund, has today announced the addition of Michael Wasserman as a Managing Partner, joining Founder John Ruffolo and Mark Maybank. Michael is returning to Canada after 17 years at H.I.G Capital Management, a leading global private equity investment firm with more than $44 billion of equity capital under management. Most recently, Michael was a Managing Director of H.I.G. BioHealth Partners, the firm's dedicated healthcare investment fund, where

Apr 23, 2021 07:30 am ET

Knight Therapeutics to Acquire Regional Rights to Exelon®

Knight Therapeutics Inc. (TSX: GUD) ("Knight") a pan-America (ex-USA) specialty pharmaceutical company, today announced that it has entered into a definitive agreement under which Knight will acquire the exclusive rights to manufacture, market and...

Apr 13, 2021 05:44 pm ET

Knight to Present at the 2021 Bloom Burton & Co. Healthcare Virtual Investor Conference

Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-US) specialty pharmaceutical company, announced today that Samira Sakhia, President and Chief Operating Officer, is scheduled to present a corporate update at the Bloom...

Mar 25, 2021 07:30 am ET

Knight Therapeutics Reports Fourth Quarter and Year End 2020 Results

Mar 18, 2021 07:30 am ET

Notice of Knight Therapeutics' Fourth Quarter 2020 Results Conference Call

Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its fourth quarter 2020 financial results on Thursday, March 25, 2021 prior to market opening. Following the release,...

Mar 01, 2021 07:04 pm ET

Knight Therapeutics Announces Canadian Commercial Launch of IBSRELA™ - New Innovative Treatment for Irritable Bowel Syndrome with Constipation

Knight Therapeutics Inc. (TSX: GUD), (“Knight”) a pan-American (ex-USA) specialty pharmaceutical company, announced today the Canadian commercial availability of IBSRELA (tenapanor), a first-in-class therapy for the treatment of irritable bowel...

Dec 23, 2020 06:08 pm ET

Knight Announces Filing of Final Base Shelf Prospectus

Knight Therapeutics Inc. (TSX: GUD) (“Knight”) today has filed and has obtained a receipt for a (final) short form base shelf prospectus (the “Shelf Prospectus”). The Shelf Prospectus was filed with the securities regulatory authorities in each of...

Dec 11, 2020 04:15 pm ET

S&P Dow Jones Indices Announces Changes to the S&P/TSX Composite Index

TORONTO, Dec. 11, 2020 /CNW/ - As a result of the quarterly review, S&P Dow Jones Indices will make the following changes in the S&P/TSX Composite Index prior to the open of trading on Monday, December 21, 2020:

Dec 10, 2020 02:40 pm ET

Knight Announces Filing of Preliminary Base Shelf Prospectus

Knight Therapeutics Inc. (TSX: GUD) (“Knight”) filed a preliminary short form base shelf prospectus with securities regulatory authorities in each of the provinces of Canada. Once a receipt for the final short form base shelf prospectus (“Shelf...

Nov 13, 2020 07:30 am ET

Knight Therapeutics Reports Third Quarter 2020 Results

Nov 06, 2020 07:30 am ET

Notice of Knight Therapeutics' Third Quarter 2020 Results Conference Call

Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its third quarter 2020 financial results on Friday, November 13, 2020 prior to market opening. Following the release,...

Oct 26, 2020 07:30 am ET

Knight Signs New Exclusive AmBisome® Agreement with Gilead in Brazil

Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a leading pan-American (ex-US) specialty pharmaceutical company, today announced the signing of a new exclusive distribution agreement with Gilead Sciences, Inc. (“Gilead”) for the commercialization...

Sep 21, 2020 05:01 pm ET

Knight and TherapeuticsMD Announce Health Canada Approval of BIJUVA®

Knight Therapeutics Inc. (TSX: GUD) (“Knight”) and TherapeuticsMD, Inc. (NASDAQ: TXMD) (“TherapeuticsMD”) announced today the approval of BIJUVA® (estradiol and progesterone) capsules by Health Canada. In Canada, BIJUVA is indicated for the...

Sep 03, 2020 05:15 pm ET

Knight Therapeutics Announces Filling of Supplement to a New Drug Submission for NERLYNX® (neratinib) to Treat HER2-Positive Metastatic Breast Cancer

Knight Therapeutics Inc. (TSX:GUD) ("Knight"), a pan-American (ex-US) specialty pharmaceutical company, announced filing of the Supplement to a New Drug Submission (SNDS) of NERLYNX for HER2-Positive Metastatic Breast Cancer in Canada. NERLYNX was...

Aug 25, 2020 07:30 am ET

Knight and TherapeuticsMD Announce Health Canada Approval of IMVEXXY®

Aug 25, 2020 07:30 am ET

Knight and TherapeuticsMD Announce Health Canada Approval of IMVEXXY®

Knight Therapeutics Inc. (TSX: GUD) (“Knight”) and TherapeuticsMD, Inc. (NASDAQ: TXMD) (“TherapeuticsMD”) announced today the approval of IMVEXXY® by Health Canada. In Canada, IMVEXXY is for the treatment of postmenopausal moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy (VVA). VVA is a prevalent, chronic, and progressive condition associated with menopause. Common symptoms of VVA include dryness, discomfort, and pain in the vaginal and vulvar areas1-4. IMVEXXY is an applicator-free, estradiol softgel vaginal capsule indicated for postmenopausal wom

Aug 14, 2020 06:45 pm ET

Knight Therapeutics Completes the Tender Offer for Grupo Biotoscana And Achieves Over 95% Ownership

Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a leading pan-American (ex-US) specialty pharmaceutical company, today announced the results of the tender offer process (“Tender Offer”) for the acquisition of all outstanding Brazilian Depositary...

Aug 13, 2020 07:30 am ET

Knight Therapeutics Reports Second Quarter 2020 Results

Aug 06, 2020 07:30 am ET

Notice of Knight Therapeutics' Second Quarter 2020 Results Conference Call

Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its second quarter 2020 financial results on Thursday, August 13, 2020 prior to market opening. Following the release,...

Jul 15, 2020 07:30 am ET

Knight Therapeutics Announces the Launch of the Tender Offer for remaining 48.8% of Grupo Biotoscana

Knight Therapeutics Inc. (TSX: GUD) and its wholly owned subsidiary 1178991 CANADA INC. ("Knight") today announced the launch of the tender offer and the release of the notice for the tender offer process filed by 1178991 CANADA INC. for the...

Jul 10, 2020 07:30 am ET

Knight Announces Normal Course Issuer Bid

Knight Therapeutics Inc. (TSX:GUD) (“Knight” or the “Company ”), a leading pan-American (ex-US) specialty pharmaceutical company, announced today acceptance by the Toronto Stock Exchange (the "TSX") of the Company's Notice of Intention to Make a...

Jul 08, 2020 05:01 pm ET

Knight Therapeutics Announces CVM Approval of the Tender Offer for remaining 48.8% of Grupo Biotoscana

Knight Therapeutics Inc. (TSX: GUD) and its wholly owned subsidiary 1178991 CANADA INC. ("Knight" or “Offeror”) today announced that the Brazilian Securities and Exchange Commission (Comissão de Valores Mobiliários) (“CVM”) has approved the Tender...

Jun 26, 2020 07:30 am ET

Knight Therapeutics Reports First Quarter 2020 Results

Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a leading pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its first quarter ended March 31, 2020. All currency amounts are in thousands...

Jun 25, 2020 10:45 pm ET

Knight Therapeutics Inc. announces voting results from the Annual Meeting

Knight Therapeutics Inc. (TSX:GUD) ("Knight" or the "Corporation") a leading pan-American (ex-US) specialty pharmaceutical company, announced today the voting results from the Annual Meeting of the Shareholders held in Montreal, Quebec ("Meeting")....

Jun 18, 2020 06:30 pm ET

Notice of Knight Therapeutics' First Quarter 2020 Results Conference Call

Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its first quarter 2020 financial results on Friday, June 26, 2020 prior to market opening. Following the release, Knight...

May 29, 2020 05:01 pm ET

Knight Therapeutics Inc. Announces Further Update on Extension of First Quarter 2020 Filings due to COVID-19

Knight Therapeutics Inc. (TSX:GUD) (“Knight” or the “Company”), a leading pan-American (ex USA) specialty pharmaceutical company, announced today, further to its news release dated April 30, 2020, that as a result of the COVID-19 impact, Knight...

May 27, 2020 05:01 pm ET

Knight to Present at the Jefferies 2020 Virtual Global Healthcare Conference

Knight Therapeutics Inc. (TSX: GUD), a leading pan-American (ex- US) specialty pharmaceutical company, announced today that Samira Sakhia, President, is scheduled to present at the Jefferies 2020 Virtual Global Healthcare Conference on Wednesday,...

Apr 30, 2020 05:01 pm ET

Knight Therapeutics Inc. Announces Extension of First Quarter 2020 Filings due to COVID-19

Knight Therapeutics Inc. (TSX:GUD) (“Knight” or the “Company”), a leading pan-American (ex USA) specialty pharmaceutical company, announced today that as a result of the COVID-19 impact, Knight will be relying on the temporary relief afforded by...

Apr 20, 2020 07:30 am ET

Knight Announces the Re-Launch of Trelstar® in Canada

Knight Therapeutics Inc., (TSX: GUD) (“Knight”) a pan-American (ex-USA) specialty pharmaceutical company, announced today that it has successfully taken over commercial activities from Debiopharm’s previous partner, Allergan. Knight licensed the...

Apr 17, 2020 07:30 am ET

Knight Therapeutics Announces Approval of IBSRELA™ in Canada

Knight Therapeutics Inc., (TSX: GUD) (“Knight”) a pan-American (ex-USA) specialty pharmaceutical company, announced that Health Canada has approved IBSRELA™ (tenapanor) for the treatment of irritable bowel syndrome with constipation (IBS-C) in...

Apr 16, 2020 07:00 am ET

Knight Therapeutics Inc. Announces Triumvira Loan Repayment

Knight Therapeutics Inc. (TSX:GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, announced today that privately-held Triumvira Immunologics Inc. ("Triumvira") has repaid the outstanding loan balance of US$5 million...

Apr 15, 2020 08:30 pm ET

Knight Therapeutics Inc. Announces Completion of its Normal Course Issuer Bid

Knight Therapeutics Inc. (TSX:GUD) ("Knight" or the "Company "), a leading pan-American (ex-USA) specialty pharmaceutical company, is pleased to announce the completion of its Normal Course Issuer Bid (“NCIB”) launched in July 2019. The...

Apr 09, 2020 10:00 pm ET

Knight Therapeutics Files Annual Information Form

Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, has filed its Annual Information Form for the year ended December 31, 2019 today. Knight had previously announced that as a result of...

Mar 30, 2020 05:01 pm ET

Knight Therapeutics Reports Fourth Quarter and Year End 2019 Results

Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a leading pan-American (ex-USA) specialty pharmaceutical company, today reported financial results for its fourth quarter and year ended December 31, 2019. All currency amounts are in thousands except...

Mar 27, 2020 07:00 pm ET

Notice of Knight Therapeutics' Fourth Quarter 2019 Results Conference Call and update due to COVID-19 pandemic

Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its fourth quarter 2019 financial results on Monday, March 30, 2020 after market closing. Following the release, Knight...

Mar 16, 2020 05:00 pm ET

Knight Announces Closing of Separation Agreement

Knight Therapeutics Inc. (TSX: GUD) ("Knight") and Medison Biotech (1995) Ltd. (“Medison”) have closed today the previously disclosed transaction to separate their respective businesses. As announced on November 21, 2019, Knight and Medison have...

Feb 11, 2020 05:00 pm ET

Quebec, New Brunswick, Newfoundland, Nova Scotia and Manitoba join Alberta, Saskatchewan, in adding Knight’s PROBUPHINE® to their provincial drug plans in the fight against the opioid crisis

Knight Therapeutics Inc. (TSX:GUD) ("Knight"), a leading pan-American (ex-USA) specialty pharmaceutical company, announced today that PROBUPHINE®, the first and only subdermal implant approved in Canada, is now additionally publicly funded in...

Jan 08, 2020 08:00 am ET

Knight Partners with Debiopharm for the Commercialization of Trelstar® in Canada

Knight Therapeutics Inc., (TSX: GUD) (“Knight”) a pan-American (ex-USA) specialty pharmaceutical company and Debiopharm , a swiss-based, global biopharmaceutical company, today announced that they have entered into an exclusive agreement that...

Jan 07, 2020 04:30 pm ET

Knight to Present at the J.P. Morgan Healthcare Conference in San Francisco

Knight Therapeutics Inc. (TSX: GUD) ("Knight") a leading pan-American (ex-USA) specialty pharmaceutical company, announced today that Samira Sakhia, President and Chief Financial Officer, is scheduled to present at the J.P. Morgan Healthcare...

Dec 20, 2019 05:05 pm ET

Knight Therapeutics Announces Submission to B3 S.A. For Unified Tender Offer

Knight Therapeutics Inc. (TSX: GUD) and its wholly owned subsidiary 1178991 CANADA INC. ("Knight" or “Offeror”) today announced that, further to its acquisition of a controlling interest (the “Transfer of Control”) in Biotoscana Investments S.A....

Nov 29, 2019 05:00 pm ET

Knight Therapeutics Announces Closing of Previously Announced Acquisition of Grupo Biotoscana

Knight Therapeutics Inc. (TSX: GUD) ("Knight") today announced that it has completed the acquisition of a 51.2% interest in Biotoscana Investments S.A. (B3: GBIO33) (“GBT” or “Grupo Biotoscana”) from a controlling shareholder group that includes...

Nov 26, 2019 07:30 am ET

Knight and TherapeuticsMD Announce Filing of New Drug Submission for Bijuva® in Canada

Knight Therapeutics Inc. (TSX: GUD) (“Knight”) and TherapeuticsMD, Inc. (NASDAQ: TXMD) (“TherapeuticsMD”) announced today that Knight's New Drug Submission (NDS) for Bijuva® has been accepted for review by Health Canada. Bijuva is a bio-identical*...

Nov 25, 2019 04:15 pm ET

Profound Medical Announces Health Canada Approval of TULSA-PRO®

Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and closed-loop...

Nov 21, 2019 05:00 pm ET

GUD Medison Resolved

Knight Therapeutics Inc. (TSX: GUD) ("Knight") and Medison Biotech (1995) Ltd. (“Medison”) announced today that they have agreed to separate their businesses and allow each of the companies to focus on growing their respective businesses...

Nov 12, 2019 05:22 pm ET

Knight Therapeutics Reports Third Quarter 2019 Results

Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a Canadian specialty pharmaceutical company, today reported financial results for its third quarter ended September 30, 2019. All currency amounts are in thousands except for share and per share...

Nov 05, 2019 07:30 am ET

Notice of Knight Therapeutics' Third Quarter 2019 Results Conference Call

Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, will release its third quarter 2019 financial results on Tuesday, November 12, 2019 after market closing. Following the release, Knight will hold a...

Oct 30, 2019 05:05 pm ET

Knight and TherapeuticsMD Announce Filing of New Drug Submission for Joyesta™ in Canada

Knight Therapeutics Inc. (TSX: GUD) (“Knight”) and TherapeuticsMD, Inc. (NASDAQ: TXMD) (“TherapeuticsMD”) announced today that Knight's New Drug Submission (NDS) for Joyesta™ has been accepted for review by Health Canada. Joyesta, licensed from TherapeuticsMD, is an applicator-free estradiol softgel vaginal capsule for the treatment of postmenopausal symptoms of vulvar and vaginal atrophy due to estrogen deficiency. Joyesta is marketed as IMVEXXY® (estradiol vaginal inserts) by TherapeuticsMD in the U.S., for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atro

Oct 30, 2019 05:01 pm ET

Knight and TherapeuticsMD Announce Filing of New Drug Submission for Joyesta™ in Canada

Oct 23, 2019 07:00 am ET

Knight Therapeutics and SIFI S.p.A. Announce Approval of NETILDEX™ in Canada

Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, and SIFI S.p.A. (“SIFI”), a prominent Italian Eye Care company, today announced that Health Canada has approved NETILDEX® for the treatment of...

Oct 21, 2019 07:00 am ET

Knight Therapeutics to Acquire Grupo Biotoscana, Establishing a Latin American Growth Platform

Knight Therapeutics Inc. (TSX: GUD) ("Knight") today announced that it has entered into a definitive agreement under which Knight will acquire a 51.21% interest in Biotoscana Investments S.A. (B3: GBIO33) (“GBT” or “Grupo Biotoscana”) from a...

Sep 03, 2019 02:37 pm ET

Medison Urges Knight Therapeutics and Jonathan Goodman to Aggressively Pursue Opportunities Created by Distressed Opioid Case Targets

Medison Biotech (1995) Ltd. (“Medison”), which together with its affiliates owns more than 10.4 million shares or 7.5% of Knight Therapeutics, Inc. (TSX:GUD) (“Knight” or the “Company”), today commented on the recent claims brought against various pharma companies in the United States and Canada (including against Joddes and Pharmascience, the Goodman family businesses in which Jonathan Goodman, Knight’s CEO, personally owns at least a 25% interest).

Aug 26, 2019 08:00 am ET

Israeli Courts Rule Against Knight Therapeutics’ and Jonathan Goodman in Frivolous and Costly Litigation Aimed at Silencing Medison

Medison Biotech (1995) Ltd. (“Medison”), which together with its affiliates owns more than 10.4 million shares or 7.5% of Knight Therapeutics, Inc. (TSX:GUD) (“Knight” or the “Company”), received a favorable ruling from Israeli courts in response to a frivolous and costly litigation claim brought by Knight CEO, Jonathan Goodman, against Medison in an attempt to silence Medison with respect to Knight’s lack of performance and poor corporate governance.

Aug 09, 2019 08:00 am ET

Medison Expresses Concerns over Knight Therapeutics' Second Quarter Results and Demands Answers to Critical Questions from Jonathan Goodman

PETACH TIKVA, Israel, Aug. 9, 2019 /CNW/ - Medison Biotech (1995) Ltd. ("Medison"), which together with its affiliates owns more than 10.4 million shares or 7.5% of Knight Therapeutics, Inc. (TSX:GUD) ("Knight" or the "Company"), demands answers from Knight and Jonathan Goodman regarding Knight's second quarter financial statements and governance related issues. Medison believes the owners of Knight deserve better and should ask the following questions:

Aug 08, 2019 06:00 am ET

Knight Therapeutics Reports Second Quarter 2019 Results

Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a Canadian specialty pharmaceutical company, today reported financial results for its second quarter ended June 30, 2019. All dollar amounts are in thousands except for share and per share amounts....

Aug 06, 2019 08:30 am ET

Knight Announces Early Warning Filing Regarding Disposition of Shares of Crescita

This press release is being disseminated by Knight Therapeutics Inc. ("Knight") (TSX:GUD), a specialty pharmaceutical company, as required by National Instrument 62-103 - The Early Warning System and Related Take Over Bid and Insider Reporting...

Aug 06, 2019 08:30 am ET

Knight Therapeutics and pan-Canadian Pharmaceutical Alliance (pCPA) Reach Agreement for PROBUPHINE® for Opioid Dependence

Knight Therapeutics Inc. (TSX:GUD) ("Knight"), a leading Canadian specialty pharmaceutical company, announced today that it has reached an agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for a Letter of Intent (LOI) regarding...

Aug 01, 2019 08:30 am ET

Notice of Knight Therapeutics' Second Quarter 2019 Results Conference Call

Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, will release its second quarter 2019 financial results on Thursday, August 8, 2019 prior to market opening. Following the release, Knight will hold...

Jul 18, 2019 08:00 am ET

Medison Biotech Considers Requisition of Special Meeting of Shareholders of Knight Therapeutics Inc.

Medison Biotech (1995) Ltd. and its affiliates (“Medison”) own or control more than 10.4 million shares of Knight Therapeutics Inc. (the “Company”), representing approximately 7.3% of the total issued shares of the Company.

Jul 16, 2019 04:30 pm ET

Knight Therapeutics Announces Health Canada Has Approved NERLYNX ® for Early-Stage Breast Cancer

Knight Therapeutics Inc. (TSX:GUD) ("Knight"), a leading Canadian specialty pharmaceutical company, announced today that Health Canada has approved NERLYNX® (neratinib) for the extended adjuvant treatment of women with early-stage hormone receptor...

Jul 09, 2019 08:41 am ET

Medison Biotech: Jonathan Goodman Takes Advantage of His Own Failure to Create Value, Enriching Himself at the Expense of the Shareholders of Knight Therapeutics

Medison Biotech (1995) Ltd. (“Medison”), which together with its affiliates owns more than 10.4 million shares or 7.3% of Knight Therapeutics, Inc. (TSX:GUD) (“Knight” or the “Company”), today commented on the recent disclosure by Knight that it intends to make a Normal Course Issuer Bid ("NCIB") for up to 12,053,693 common shares of the Company, being approximately 10% of its public float.

Jul 08, 2019 05:00 pm ET

Knight Announces Normal Course Issuer Bid

Knight Therapeutics Inc. (TSX:GUD) (“Knight” or the “Company ”), a leading Canadian specialty pharmaceutical company, announced today acceptance by the Toronto Stock Exchange (the "TSX") of the Company's Notice of Intention to Make a Normal Course...

Jun 26, 2019 08:30 am ET

Knight Announces Filing of New Drug Submission for Ibsrela™ in Canada

Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a Canadian specialty pharmaceutical company, announced today that Knight's New Drug Submission (NDS) for Ibsrela™ (tenapanor) has been accepted for review by Health Canada for the treatment of...

Jun 25, 2019 08:30 am ET

Medison Establishes Canada’s Only Innovative Pharma Commercial Company

Medison Biotech (1995) Ltd. (“Medison”), today announced the appointment of Mr. Joe O’Neill as General Manager of Medison Canada. Headquartered in Toronto, Canada, Medison Canada is the only specialized pharmaceutical and biotech company in Canada purely focused on licensing highly innovative, cutting edge therapeutics for patients in need of life saving therapies. Medison (and its affiliates) are also the second largest shareholders of Knight therapeutics (TSX:GUD).

Jun 19, 2019 09:34 am ET

Medison Issues Open Letter to Knight Therapeutics Shareholders Urging Jonathan Goodman to Build Real Business during the Grace Period Knight Received

Medison Biotech (1995) Ltd. (“Medison”), which together with its affiliates owns more than 10.4 million shares or 7.3% of Knight Therapeutics, Inc. (TSX:GUD) (“Knight” or the “Company”), today issued the following open letter from Medison CEO Meir Jakobsohn on Knight’s continued underperformance and conflicts of interest:

Jun 18, 2019 05:00 pm ET

Knight has less skin in Medimetriks through full loan repayment

Knight Therapeutics Inc. (TSX:GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, announced today that Medimetriks Pharmaceuticals Inc. (“Medimetriks”) has prepaid the remaining US$750 thousand balance of Knight’s US$23 million...

Jun 11, 2019 04:00 pm ET

Knight to Present at the Raymond James Life Sciences and MedTech Conference in New York City

Knight Therapeutics Inc. (TSX: GUD), a leading Canadian specialty pharmaceutical company, announced today that Jonathan Ross Goodman, Chief Executive Officer, is scheduled to present at the Raymond James Life Sciences and MedTech Conference on...

May 28, 2019 04:00 pm ET

Knight to Present at the Jefferies 2019 Global Healthcare Conference in New York City

Knight Therapeutics Inc. (TSX: GUD), a leading Canadian specialty pharmaceutical company, announced today that Jonathan Ross Goodman, Chief Executive Officer, is scheduled to present at the Jefferies 2019 Global Healthcare Conference on Tuesday,...

May 23, 2019 03:48 pm ET

Knight to Present at the National Bank Financial Markets 9th Annual Quebec Conference in Toronto

Knight Therapeutics Inc. (TSX: GUD), a leading Canadian specialty pharmaceutical company, announced today that Samira Sakhia, President and Chief Financial Officer is scheduled to participate in a fireside chat at the National Bank Financial...

May 15, 2019 05:54 pm ET

Knight to Present at the 2019 RBC Capital Markets Global Healthcare Conference in New York City

Knight Therapeutics Inc. (TSX: GUD), a leading Canadian specialty pharmaceutical company, announced today that Jonathan Ross Goodman, Chief Executive Officer, Samira Sakhia, President and Chief Financial Officer and Amal Khouri, Vice President of...

May 09, 2019 06:00 am ET

Knight Reports First Quarter 2019 Results

Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a Canadian specialty pharmaceutical company, today reported financial results for its first quarter ended March 31, 2019. All dollar amounts are in thousands except for share and per share amounts....

May 07, 2019 08:21 pm ET

GUD Day for Knight: Shareholders Vote Overwhelmingly in Favour of Management

Knight Therapeutics Inc. (TSX:GUD) ("Knight" or the "Corporation"), a Canadian specialty pharmaceutical company, announced today the voting results from the Annual Meeting of the Shareholders ("Meeting") held in Montreal, Quebec. Election of...

May 07, 2019 06:49 pm ET

Medison Creates Significant Change at Knight Therapeutics

May 03, 2019 07:00 am ET

Medison Campaign Successfully Creates Unanimous Consent for Change at Knight Therapeutics

Medison Biotech (1995) Ltd. (“Medison”), which together with its affiliates owns more than 10.4 million shares or 7.3% of Knight Therapeutics, Inc. (TSX:GUD) (“Knight” or the “Company”), today issued the following open letter regarding the strong momentum for change it has created through its campaign. Further it detailed its intention if its nominees are unable to achieve Board representation with the ability to effect meaningful change, including pledging to pursue a Diamond strategy in Canada through a new company, indepe

May 02, 2019 08:00 am ET

Notice of Knight Therapeutics' First Quarter 2019 Results Conference Call

Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, will release its first quarter 2019 financial results on Thursday, May 9, 2019 prior to market opening. Following the release, Knight will hold a...

May 01, 2019 08:00 am ET

As Deadline Approaches, Knight Therapeutics Reminds Shareholders to Vote the BLUE Proxy for Nominees Who Support Jonathan Goodman’s Vision

Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a Canadian specialty pharmaceutical company, thanks shareholders for their overwhelming support ahead of the upcoming Annual Meeting of Shareholders and encourages all shareholders who haven’t yet...

Apr 30, 2019 06:30 am ET

Medison Urges Knight Shareholders to Demand Answers to Critical Questions from Jonathan Goodman at the Bloom Burton & Co. Healthcare Investor Conference

Medison Biotech (1995) Ltd. (“Medison”), which together with its affiliates owns more than 10.4 million shares or 7.3% of Knight Therapeutics, Inc. (TSX:GUD) (“Knight” or the “Company”), today noted that Knight CEO Jonathan Goodman is presenting at the Bloom Burton & Co. Healthcare Investor Conference at 930 AM ET. The conference is being held at 255 Front Street West – MTCC North Building (Lower Level 100). Medison urges Knight shareholders to demand answers from Knight and Jonathan Goodman regarding ongoing governance prob

Apr 29, 2019 08:45 am ET

Medison Urges Fellow Shareholders to Bring Positive Change to Knight Therapeutics by Voting for All Six of Medison's Highly Qualified Nominees at Upcoming Annual Meeting

Failures at Knight have been exposed by multiple, independent third parties Change can only be assured if all Medison nominees are elected Conflicts, related-party transactions and an on-going failure to create value for shareholders must come to an end Medison also calls on Knight shareholders to vote FOR Medison's proposed Enhanced Governance Bylaw to strengthen governance and eliminate current conflicts among Board and CEO PETACH TIKVA, Israel, April 29, 2019 /CNW/ - Medison Biotech (1995) Ltd. ("Medison"), which together with its affiliates owns more than 10.4 million shares or 7.3% of

Apr 26, 2019 10:56 pm ET

Second Leading Independent Proxy Advisory Firm Supports Medison and Recommends Change and a New Strategy at Knight Therapeutics

Medison Biotech (1995) Ltd. (“Medison”), which together with its affiliates owns more than 10.4 million shares or 7.3% of Knight Therapeutics, Inc. (TSX:GUD) (“Knight” or the “Company”), today announced that Glass Lewis & Co., LLC, a leading independent proxy advisory firm, has noted the underperformance of Knight, severe conflicts of interest among the directors, management and the Goodman family and the need for change to the Knight Board of Directors. Glass Lewis recommends that shareholders vote for change by using the G

Apr 26, 2019 07:24 pm ET

Second Leading Proxy Advisor Rejects Meir Jakobsohn’s Attempt to Take Control of Knight Therapeutics’ Board

Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a Canadian specialty pharmaceutical company, today announced that leading independent proxy advisory firm Glass, Lewis & Co., LLC (“Glass Lewis”) has recommended that shareholders reject Meir...

Apr 26, 2019 08:00 am ET

Knight to Present at the 2019 Bloom Burton & Co. Healthcare Investor Conference in Toronto

Knight Therapeutics Inc. (TSX: GUD), a leading Canadian specialty pharmaceutical company, announced today that Jonathan Ross Goodman, Chief Executive Officer and Samira Sakhia, President and Chief Financial Officer, are scheduled to present a...

Apr 25, 2019 01:36 pm ET

Leading Independent Proxy Advisor, Key Shareholders, and More Analysts Back Jonathan Goodman’s Knight, Recommend Meir Jakobsohn Not be Re-elected to the Board

Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a Canadian specialty pharmaceutical company, today announced that leading independent proxy advisory firm Institutional Shareholder Services Inc. ("ISS") has joined equity analysts and a growing...

Apr 25, 2019 10:21 am ET

Leading Independent Proxy Advisory Firm ISS Recommends Change at Knight Therapeutics

ISS Notes "Stark" Underperformance, Recommends Election of New Independent Directors and for Knight Shareholders to Vote on the GOLD Proxy Card

Apr 25, 2019 08:00 am ET

Knight Therapeutics Releases New Letter to Shareholders, Reminds Shareholders of Important Vote

Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a Canadian specialty pharmaceutical company, today mailed and filed on SEDAR a letter to shareholders ahead of the upcoming 2019 Annual Meeting of Shareholders (the “Meeting”) on May 7, 2019. The...

Apr 18, 2019 09:00 am ET

Medison Issues Presentation to Knight Shareholders

Makes Case for Urgent Change, Improved Governance and a Common-Sense Strategic Growth Plan Details History of Failed Execution, Underperformance and Conflicts of Interest Under Current Board and CEO Provides Background on Experienced, Independent Director Nominees That Can Effect Positive Change Rebuts Knight's Campaign of Misinformation and Harassment Against Shareholders PETACH TIKVA, Israel, April 18, 2019 /CNW/ - Medison Biotech (1995) Ltd. ("Medison"), which together with its affiliates owns more than 10.4 million shares or 7.3% of Knight Therapeutics, Inc. (TSX:GUD) ("Knight" or the "

Apr 17, 2019 07:00 am ET

Leading Canadian Corporate Governance Expert Confirms Acute Board Conflicts and Governance Deficiencies at Knight Therapeutics

Report includes 54 recommended governance improvements for Knight and is available to all investors

Apr 16, 2019 08:30 am ET

Medison Issues Letter to Shareholders of Knight Therapeutics, Outlining Qualified, Independent Director Nominees and Common-Sense Plan to Build Value

Knight has a tremendous opportunity to create value, but is currently on the wrong path Medison's experienced and independent director nominees are committed to pursuing a common-sense, low-risk plan that creates value for all shareholders More information on the director nominees and Medison's comprehensive plan for Knight, including plans to return at least $100 million of excess capital to Knight shareholders in the form of a special dividend or share buyback, is available at www.NewDayForKnight.com PETACH TIKVA, Israel, April 16, 2019 /CNW/ - Medison Biotech (1995) Ltd. ("Medison"), wh

Apr 12, 2019 05:00 pm ET

Knight Therapeutics: Use of PROBUPHINE™ for Opioid Disorder Gains Momentum Across Canada; Subdermal Implant Now in Use from Coast to Coast

Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a Canadian specialty pharmaceutical company, is pleased to announce that PROBUPHINE™, a new treatment in the fight against opioid addiction, is now being implanted in patients across the country....

Apr 10, 2019 06:40 pm ET

Knight Receives Unanimous Support from Independent Analysts for Director Nominees, Current Strategy

Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a Canadian specialty pharmaceutical company, thanks a rapidly growing list of shareholders and the analyst community for overwhelming support ahead of the upcoming 2019 Annual Meeting of Shareholders...

Apr 10, 2019 08:39 am ET

Medison Disappointed that Knight Therapeutics has Resorted to Blatant Misrepresentations to Avoid Scrutiny

Knight is a failure, with a floundering share price and minimal progress at building an operating business Apparently unable to respond to Medison's criticisms on the merits, Knight has wasted corporate assets and harassed Medison with spurious litigation, demanded thousands of documents, and has mounted a dishonest and hypocritical proxy campaign defense Medison urges Knight shareholders to remain focused on the fact that Knight's stock has produced no returns for shareholders for more than three years and implies little or no value for Knight's operating business Medison encourages shareho

Apr 08, 2019 08:00 am ET

Medison Files Proxy Circular, Offers Knight Therapeutics Shareholders Truly Independent, Unconflicted Directors and Comprehensive Business Plan to Fix a Failing Knight

Knight has failed to build a meaningful business or create long-term shareholder value, despite tremendous opportunities and unprecedented resourcesKnight share price has been floundering for over three years, significantly underperforming other pharmaceutical companiesCurrent Board and CEO are conflicted and entrenched, wasting corporate assets by attacking shareholders in an attempt to divert attention from the Company's poor execution and performanceMedison has developed a comprehensive plan to help Knight become a growing and profitable Canadian-based pharmaceutical company by 2025; new

Apr 08, 2019 07:00 am ET

Knight Therapeutics Continues to Demonstrate Winning Strategy; Files Investor Presentation, Launches Microsite

Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a Canadian specialty pharmaceutical company, announced today it has filed an investor presentation on SEDAR and on its website in connection with its 2019 Annual Meeting of Shareholders (the...

Apr 04, 2019 08:45 am ET

Knight Files Management Information Circular, Warns Shareholders of Activist Jakobsohn’s Self-Interested Agenda

Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a Canadian specialty pharmaceutical company, announced today that the Company has filed its management information circular (the “Circular”) for its upcoming 2019 Annual General Meeting (the...

Apr 01, 2019 08:00 am ET

Medison to Nominate Six Highly Qualified Directors for Knight Therapeutics' Board to Strengthen Oversight and Drive Value Creation for All Shareholders

Knight is failing, its CEO and Board are conflicted and shareholders are suffering as a result Medison's independent nominees are accomplished industry veterans who can objectively oversee and guide Knight More information on the director nominees and Medison's comprehensive plan for Knight, including plans to return at least $100 million of excess capital to Knight shareholders in the form of a special dividend or share buyback, is available at www.NewDayForKnight.com PETACH TIKVA, Israel, April 1, 2019 /CNW/ - Medison Biotech (1995) Ltd. ("Medison"), which together with its affiliates ow

Mar 21, 2019 08:00 am ET

Knight Therapeutics Initiates Legal Action Against Medison Biotech to Protect the Interests of Knight Shareholders

Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a Canadian specialty pharmaceutical company, today announced that it has initiated a lawsuit in District Court Center-Lod in Israel against Medison Biotech Ltd. ("Medison"), its CEOMeir Jakobsohn, and...

Mar 15, 2019 07:40 am ET

Knight Therapeutics Responds to Shareholder Discontent By Targeting Medison Biotech, Knight’s Second Largest Shareholder

Medison Biotech Ltd. (“Medison”), which together with its affiliates owns more than 10.4 million shares, or 7.3% of Knight Therapeutics, Inc. (TSX:GUD) (“Knight” or the “Company”) today released correspondence it received from Knight’s lawyers and...

Mar 14, 2019 08:30 pm ET

Knight Addresses Misleading and Self-Serving Plan Issued by Disgruntled Director

Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a Canadian specialty pharmaceutical company, today issued the following statement addressing a press release and presentation from Medison Biotech Ltd. (“Medison”) and its CEO, Meir Jakobsohn, who is...

Mar 14, 2019 08:00 am ET

Knight Therapeutics’ Second Largest Shareholder Presents Strategy to Create Shareholder Value

Medison Biotech Ltd. (“Medison”), which together with its affiliates owns more than 10.4 million shares, or 7.3% of Knight Therapeutics, Inc. (TSX:GUD) (“Knight” or the “Company”) has presented a detailed and compelling plan to the Company’s Board...

Mar 14, 2019 06:00 am ET

Knight Reports 2018 Fourth Quarter and Year End Results

Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a Canadian specialty pharmaceutical company, today reported financial results for its fourth quarter and year ended December 31, 2018. All dollar amounts are in thousands except for share and per...

Mar 07, 2019 05:01 pm ET

Notice of Knight Therapeutics' 2018 Fourth Quarter and Year End Results Conference Call

Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, will release its 2018 fourth quarter and year end financial results on Thursday, March 14, 2019 prior to market opening. Following the release,...

Feb 28, 2019 04:53 pm ET

Knight Therapeutics Comments on Flawed Accusations by Disgruntled Board Member; Remains Committed to Executing Strategy that is Working

Knight Therapeutics Inc. (TSX: GUD) ("Knight" or the “Company”), a leading Canadian specialty pharmaceutical company, confirms it is aware of statements made by Mr. Meir Jakobsohn regarding Knight’s business strategy. As part of the Company’s...

Feb 20, 2019 04:05 pm ET

Knight Therapeutics and Triumvira Immunologics Triumphantly Announce Secured Bridge Loan & License Agreement

Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a Canadian specialty pharmaceutical company focused on acquiring, in-licensing, selling and marketing innovative pharmaceutical products, today announced it has entered into a secured loan and...

Feb 18, 2019 08:30 am ET

Knight Signs GUD (Bueno) Latin American Strategic Funding Deal with Moksha8

Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a Canadian specialty pharmaceutical company focused on acquiring, in-licensing, selling and marketing innovative prescription pharmaceutical products and Moksha8 Inc. (“Moksha8”), a specialty...

Feb 18, 2019 07:30 am ET

Knight Signs GUD (Bueno) Latin American Strategic Funding Deal with Moksha8

MONTREAL and BERWIN, Pennsylvania, Feb. 18, 2019 /PRNewswire/ -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a Canadian specialty pharmaceutical company focused on acquiring, in-licensing, selling and marketing innovative prescription pharmaceutical products and Moksha8 Inc. ("Moksha8"), a specialty pharmaceutical company focused on licensing and marketing innovative and established therapeutics in Latin America, today announced the closing of a strategic financing agreement for up to US $125 million.

Jan 11, 2019 08:00 am ET

Knight Therapeutics Runs with Exclusive Canadian License to Puma’s NERLYNX®

Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a Canadian specialty pharmaceutical company focused on acquiring, in-licensing, selling and marketing innovative prescription and over-the-counter pharmaceutical products, today announced it has...

Nov 26, 2018 04:30 pm ET

Knight Therapeutics Announces Canadian Regulatory Approval for ILUVIEN®

Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, today announced that Health Canada has approved ILUVIEN® for the treatment of diabetic macular edema (DME). ILUVIEN is a fluocinolone acetonide...

Nov 26, 2018 01:57 pm ET

Knight Therapeutics Reports Third Quarter 2018 Results

Knight Therapeutics Inc. (TSX:GUD) ("Knight"), a Canadian specialty pharmaceutical company, today reported financial results for its third quarter ended September 30, 2018. Q3 2018 Highlights Financials Revenues were $3,220, an increase of...

Nov 08, 2018 06:00 am ET

Knight Therapeutics Reports Third Quarter 2018 Results

Nov 01, 2018 08:00 am ET

Notice of Knight Therapeutics' Third Quarter 2018 Results Conference Call

Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, will release its third quarter 2018 financial results on Thursday, November 8th, 2018 prior to market opening. Following the release, Knight will...

Oct 29, 2018 08:00 am ET

Knight Therapeutics Announces the Canadian launch of PROBUPHINE™ for Opioid Use Disorder

Knight Therapeutics Inc. (TSX:GUD) ("Knight"), a leading Canadian specialty pharmaceutical company, announced today the commercial availability of PROBUPHINE™ (buprenorphine hydrochloride subdermal implant), for the management of opioid dependence...

Sep 25, 2018 08:00 am ET

Knight to Present at the Cantor Fitzgerald Global Healthcare Conference in New York City

Knight Therapeutics Inc. (TSX: GUD), a leading Canadian specialty pharmaceutical company, announced today that Samira Sakhia, President and Chief Financial Officer, will be presenting at the Cantor Fitzgerald Global Healthcare Conference on...

Sep 24, 2018 04:36 pm ET

Knight Therapeutics and Jaguar Health Announce Strategic Partnership

Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a Canadian-based specialty pharmaceutical company focused on acquiring, in-licensing, selling and marketing innovative prescription and over-the-counter pharmaceutical products, and Jaguar Health,...

Sep 24, 2018 04:30 pm ET

Knight Therapeutics and Jaguar Health Announce Strategic Partnership

Knight Receives License to Mytesi® and Related Products in Canada and Israel

Sep 06, 2018 09:00 am ET

Knight to Participate at the Morgan Stanley Global Healthcare Conference in New York City

Knight Therapeutics Inc. (TSX: GUD), a leading Canadian specialty pharmaceutical company, announced today that Samira Sakhia, President and Chief Financial Officer, will participate in a fireside chat at the 16th Annual Morgan Stanley Global...

Aug 31, 2018 05:31 pm ET

Knight Disposes of a Toddler-Sized Amount of Pediapharm Inc.

Aug 09, 2018 06:00 am ET

Knight Therapeutics Reports Second Quarter 2018 Results

Knight Therapeutics Inc. (TSX:GUD) ("Knight"), a leading Canadian specialty pharmaceutical company, today reported financial results for its second quarter ended June 30, 2018. Q2 2018 Highlights Financials Revenues were $2,238, a decrease of...

Aug 02, 2018 08:00 am ET

Notice of Knight Therapeutics' Second Quarter 2018 Results Conference Call

Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, will release its second quarter 2018 financial results on Thursday, August 9th, 2018 prior to market opening. Following the release, Knight will...

Jul 31, 2018 04:13 pm ET

Knight Therapeutics and TherapeuticsMD Announce Strategic Partnership

Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a Canadian specialty pharmaceutical company, and TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced that they have entered into a licensing agreement that grants Knight the rights to commercialize TX-004HR and TX-001HR in Canada and Israel.

Jul 31, 2018 04:12 pm ET

Knight Therapeutics and TherapeuticsMD Announce Strategic Partnership

Knight Therapeutics Inc. (TSX:GUD) (“Knight”), a Canadian specialty pharmaceutical company, and TherapeuticsMD, Inc. (NASDAQ:TXMD), an innovative women’s healthcare company, today announced that they have entered into a licensing agreement that...

Jul 06, 2018 08:00 am ET

Knight Receives Adverse Notice of Reassessment from CRA

Knight Therapeutics Inc. (TSX:GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, announced today that it has received a notice of reassessment (“CRA Notice”) from the Canada Revenue Agency (“CRA”) for its fiscal year ended...

Jun 05, 2018 04:30 pm ET

Knight to Present at the Jefferies Global Healthcare Conference in New York City

Knight Therapeutics Inc. (TSX:GUD), a leading Canadian specialty pharmaceutical company, announced today that Samira Sakhia, President and Chief Financial Officer, is scheduled to present a corporate update at Jefferies Global Healthcare Conference...

May 25, 2018 08:00 am ET

Knight to Present at the National Bank Financial Quebec Conference in Toronto

May 10, 2018 06:00 am ET

Knight Reports First Quarter 2018 Results

Knight Therapeutics Inc. (TSX:GUD) ("Knight"), a leading Canadian specialty pharmaceutical company, today reported financial results for its first quarter ended March 31, 2018. All dollar amounts are in thousands except for share and per share...

May 09, 2018 08:00 am ET

Knight Therapeutics Inc. announces voting results from the Annual Meeting

Knight Therapeutics Inc. (TSX:GUD) (“Knight” or the “Corporation”) announced today the voting results from the Annual Meeting of the Shareholders held in Montreal, Quebec (“Meeting”). Election of Directors Each director nominee listed in the...

May 03, 2018 08:00 am ET

Notice of Knight Therapeutics' First Quarter 2018 Results Conference Call

Knight Therapeutics Inc. (TSX:GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, will release its first quarter 2018 financial results on Thursday, May 10, 2018 prior to the market opening. Following the release, Knight will hold...

Apr 26, 2018 08:00 am ET

Knight to Blossom at Bloom Burton Conference

MONTREAL, April 26, 2018 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD), a leading Canadian specialty pharmaceutical company, announced today that Samira Sakhia, President and Chief Financial Officer, is scheduled to present a corporate update at the Bloom Burton...

Ad blocking detected

Knight Therapeutics Inc. (T:GUD)

Business Focus: Proprietary & Advanced Pharmaceuticals